ORIC PHARMACEUTICALS, INC. Operating Income
ORIC PHARMACEUTICALS, INC. (ORIC) reported Operating Income of -$45.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$45.30M.
- ORIC PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$39.62M.
- ORIC PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$34.55M.
- ORIC PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$36.67M.
- ORIC PHARMACEUTICALS, INC. operating income (loss) for fiscal 2025 was -$143.00M.
- ORIC PHARMACEUTICALS, INC. operating income (loss) for fiscal 2024 was -$142.90M.
- ORIC PHARMACEUTICALS, INC. operating income (loss) for fiscal 2023 was -$110.78M.
- ORIC PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was -$91.77M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$45.30M 10-Q · filed 2026-08-03 | -$84.92M 10-Q · filed 2026-08-03 | -$119.47M derived: sum of 3 quarters · filed 2026-08-03 | -$156.14M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$39.62M 10-Q · filed 2026-05-04 | -$74.17M derived: sum of 2 quarters · filed 2026-05-04 | -$110.84M derived: sum of 3 quarters · filed 2026-05-04 | -$149.91M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$34.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$71.22M derived: sum of 2 quarters · filed 2026-02-23 | -$110.29M derived: sum of 3 quarters · filed 2026-08-03 | -$143.00M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$36.67M 10-Q · filed 2025-11-13 | -$75.73M derived: sum of 2 quarters · filed 2026-08-03 | -$108.45M 10-Q · filed 2025-11-13 | -$148.02M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$39.06M 10-Q · filed 2026-08-03 | -$71.78M 10-Q · filed 2026-08-03 | -$111.35M derived: sum of 3 quarters · filed 2026-08-03 | -$149.67M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$32.72M 10-Q · filed 2026-05-04 | -$72.29M derived: sum of 2 quarters · filed 2026-05-04 | -$110.61M derived: sum of 3 quarters · filed 2026-05-04 | -$146.62M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$39.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$77.89M derived: sum of 2 quarters · filed 2026-02-23 | -$113.91M derived: sum of 3 quarters · filed 2026-02-23 | -$142.90M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$38.32M 10-Q · filed 2025-11-13 | -$74.33M derived: sum of 2 quarters · filed 2025-11-13 | -$103.33M 10-Q · filed 2025-11-13 | -$134.75M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$36.02M 10-Q · filed 2025-08-12 | -$65.01M 10-Q · filed 2025-08-12 | -$96.44M derived: sum of 3 quarters · filed 2025-08-12 | -$125.12M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$28.99M 10-Q · filed 2025-05-05 | -$60.42M derived: sum of 2 quarters · filed 2025-05-05 | -$89.10M derived: sum of 3 quarters · filed 2025-05-05 | -$114.09M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | -$31.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$60.11M derived: sum of 2 quarters · filed 2025-02-18 | -$85.10M derived: sum of 3 quarters · filed 2025-02-18 | -$110.78M 10-K · filed 2025-02-18 |
| 2023-09-30 | -$28.68M 10-Q · filed 2024-11-12 | -$53.67M derived: sum of 2 quarters · filed 2024-11-12 | -$79.35M 10-Q · filed 2024-11-12 | -$101.47M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$24.99M 10-Q · filed 2024-08-12 | -$50.67M 10-Q · filed 2024-08-12 | -$72.79M derived: sum of 3 quarters · filed 2024-08-12 | -$98.48M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$25.68M 10-Q · filed 2024-05-06 | -$47.80M derived: sum of 2 quarters · filed 2024-05-06 | -$73.49M derived: sum of 3 quarters · filed 2024-05-06 | -$94.19M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$22.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$47.81M derived: sum of 2 quarters · filed 2024-03-11 | -$68.51M derived: sum of 3 quarters · filed 2024-03-11 | -$91.77M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$25.69M 10-Q · filed 2023-11-06 | -$46.39M derived: sum of 2 quarters · filed 2023-11-06 | -$69.65M 10-Q · filed 2023-11-06 | -$92.45M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$20.70M 10-Q · filed 2023-08-10 | -$43.95M 10-Q · filed 2023-08-10 | -$66.76M derived: sum of 3 quarters · filed 2023-08-10 | -$85.22M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$23.26M 10-Q · filed 2023-05-08 | -$46.06M derived: sum of 2 quarters · filed 2023-05-08 | -$64.52M derived: sum of 3 quarters · filed 2023-05-08 | -$85.58M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$22.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$41.26M derived: sum of 2 quarters · filed 2023-03-16 | -$62.32M derived: sum of 3 quarters · filed 2023-03-16 | -$78.87M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$18.46M 10-Q · filed 2022-11-07 | -$39.51M derived: sum of 2 quarters · filed 2022-11-07 | -$56.07M 10-Q · filed 2022-11-07 | -$84.35M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$21.06M 10-Q · filed 2022-08-11 | -$37.61M 10-Q · filed 2022-08-11 | -$65.89M derived: sum of 3 quarters · filed 2022-08-11 | -$91.49M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$16.55M 10-Q · filed 2022-05-09 | -$44.84M derived: sum of 2 quarters · filed 2022-05-09 | -$70.44M derived: sum of 3 quarters · filed 2022-05-09 | -$81.56M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$28.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$53.88M derived: sum of 2 quarters · filed 2022-03-21 | -$65.01M derived: sum of 3 quarters · filed 2022-03-21 | -$74.19M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$25.60M 10-Q · filed 2021-11-08 | -$36.73M derived: sum of 2 quarters · filed 2021-11-08 | -$45.90M 10-Q · filed 2021-11-08 | -$54.67M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-06-30 | -$11.12M 10-Q · filed 2021-08-10 | -$20.30M 10-Q · filed 2021-08-10 | -$29.07M derived: sum of 3 quarters · filed 2022-03-21 | -$36.17M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-03-31 | -$9.18M 10-Q · filed 2021-05-06 | -$17.95M derived: sum of 2 quarters · filed 2022-03-21 | -$25.05M derived: sum of 3 quarters · filed 2022-03-21 | -$31.40M derived: sum of 4 quarters · filed 2022-03-21 |
| 2019-12-31 | -$8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$15.87M derived: sum of 2 quarters · filed 2022-03-21 | -$22.22M derived: sum of 3 quarters · filed 2022-03-21 | -$28.57M 10-K · filed 2022-03-21 |
| 2019-09-30 | -$7.10M 10-Q · filed 2020-11-05 | -$13.45M derived: sum of 2 quarters · filed 2020-11-05 | -$19.80M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$6.36M 10-Q · filed 2020-08-05 | -$12.70M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$6.35M 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | -$22.37M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |